CN104185639B - Glp-1前体药物 - Google Patents

Glp-1前体药物 Download PDF

Info

Publication number
CN104185639B
CN104185639B CN201380011989.XA CN201380011989A CN104185639B CN 104185639 B CN104185639 B CN 104185639B CN 201380011989 A CN201380011989 A CN 201380011989A CN 104185639 B CN104185639 B CN 104185639B
Authority
CN
China
Prior art keywords
glp
ethyoxyl
amino
compound
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380011989.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104185639A (zh
Inventor
J.C.诺里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN104185639A publication Critical patent/CN104185639A/zh
Application granted granted Critical
Publication of CN104185639B publication Critical patent/CN104185639B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201380011989.XA 2012-03-01 2013-02-26 Glp-1前体药物 Active CN104185639B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12157638 2012-03-01
EP12157638.3 2012-03-01
PCT/EP2013/053796 WO2013127779A1 (en) 2012-03-01 2013-02-26 Glp-1 prodrugs

Publications (2)

Publication Number Publication Date
CN104185639A CN104185639A (zh) 2014-12-03
CN104185639B true CN104185639B (zh) 2018-06-19

Family

ID=47748659

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380011989.XA Active CN104185639B (zh) 2012-03-01 2013-02-26 Glp-1前体药物

Country Status (6)

Country Link
US (1) US9452225B2 (enExample)
EP (1) EP2820038B1 (enExample)
JP (1) JP6300735B2 (enExample)
CN (1) CN104185639B (enExample)
ES (1) ES2810153T3 (enExample)
WO (1) WO2013127779A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003465A1 (en) 2015-10-28 2017-05-04 Krishna Kumar Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN109942696A (zh) * 2017-12-21 2019-06-28 中国药科大学 长效化胰高血糖素样肽－1（glp－1）类似物及其应用
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN113336840B (zh) * 2020-03-02 2022-09-23 武汉帕肽生物医药有限责任公司 订书肽、其制备方法和用途
US20210318292A1 (en) * 2020-04-13 2021-10-14 Sensorium Bio, Inc. System and Method to Detect Small Molecules
US20250268986A1 (en) 2020-11-06 2025-08-28 Novo Nordisk A/S Glp-1 prodrugs and uses thereof
CN119173275A (zh) 2022-05-10 2024-12-20 诺和诺德股份有限公司 Glp-1多肽的前药及其用途
CN120659805A (zh) * 2023-10-31 2025-09-16 深圳信立泰药业股份有限公司 Glp-1化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101220088A (zh) * 2007-09-24 2008-07-16 中国人民解放军第四军医大学 人胰高血糖素样肽-1类似物的融合蛋白及其应用
CN101910193A (zh) * 2007-12-28 2010-12-08 诺沃-诺迪斯克有限公司 Glp-1类似物的半重组制备法
CN101983066A (zh) * 2008-01-30 2011-03-02 印第安那大学科技研究公司 基于酯的肽前药

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61143400A (ja) * 1984-12-17 1986-07-01 Kenji Okawa アクチノマイシンｄ様ペプチド
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CZ2004441A3 (cs) * 2001-10-01 2004-11-10 Eli Lilly And Company Léčivo pro snižování mortality a morbidity souvisejících s kritickými onemocněními
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
CA2747195A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
RU2580317C2 (ru) * 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101220088A (zh) * 2007-09-24 2008-07-16 中国人民解放军第四军医大学 人胰高血糖素样肽-1类似物的融合蛋白及其应用
CN101910193A (zh) * 2007-12-28 2010-12-08 诺沃-诺迪斯克有限公司 Glp-1类似物的半重组制备法
CN101983066A (zh) * 2008-01-30 2011-03-02 印第安那大学科技研究公司 基于酯的肽前药

Also Published As

Publication number Publication date
EP2820038A1 (en) 2015-01-07
CN104185639A (zh) 2014-12-03
JP2015513544A (ja) 2015-05-14
ES2810153T3 (es) 2021-03-08
EP2820038B1 (en) 2020-06-17
JP6300735B2 (ja) 2018-03-28
US20150045281A1 (en) 2015-02-12
US9452225B2 (en) 2016-09-27
WO2013127779A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
CN104185639B (zh) Glp-1前体药物
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
CN104519902B (zh) 双酰化glp‑1衍生物
JP6006118B2 (ja) Ｇｌｐ−１アナログ及び誘導体
JP6687557B2 (ja) Ｇｌｐ−１様ペプチドの誘導体及びその使用
CN101868476B (zh) 胰高血糖素样肽-1衍生物及其制药用途
JP6730278B2 (ja) Ｇｌｐ−１誘導体及びその使用
CN103596972B (zh) 多肽
CN104411322B (zh) 双酰化glp‑1衍生物
JP6691125B2 (ja) Ｇｌｐ−１誘導体及びその使用
EP3033112B1 (en) Glp-1 derivatives, and uses thereof
JP7053480B2 (ja) Ｇｌｐ－１誘導体及びその使用
CN107266558A (zh) Glp‑1衍生物
CN101842386A (zh) 截短的glp-1衍生物和它们的治疗用途
KR20160021183A (ko) Glp-1 유도체 및 그것의 용도
JP2025521254A (ja) Ｃｎｐ化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Denmark bagsvaerd

Applicant after: Novo Nordisk limited company

Address before: Denmark bagsvaerd

Applicant before: NOVO NORDISK AS

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM:

Free format text: CORRECT: APPLICANT; FROM: NOVO NORDISK A/S (A/S) TO: NOVO NORDISK A/S

GR01 Patent grant
GR01 Patent grant